Search

635 Result(s)
Sort by

Trailr2-cdh17-antibody-phase1-trial

Trailr2-cdh17-antibody-phase1-trial

Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Collaborating for social impact

Collaborating for social impact

Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
Respimat re-usable wins Pharmapack Eco-Design Award

Respimat re-usable wins Pharmapack Eco-Design Award

The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
biopharmaceuticals-in-china

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.
Rabies? Not in Mexico!

Rabies? Not in Mexico!

Mexico has been a rabies-free country for the last five years. How does Mexico achieve this? Learn how we're collaborating in this fight against rabies.
BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation